Natera (NTRA) is trading higher as investors digest a favorable court decision that awards the company a 30% ongoing royalty tied to post-injunction revenues from infringing MRD-related product sales that fall within exceptions to a prior injunction. The decision was issued April 6, 2026, and reinforces Natera’s intellectual-property position in molecular residual disease (MRD) testing—an area that underpins the company’s Signatera franchise. (investor.natera.com)

An ongoing royalty framework can be more meaningful than a one-time damages headline because it potentially converts litigation outcomes into a recurring, time-extended economic benefit. With MRD adoption expanding and reimbursement and guideline momentum a key focus for investors, any incremental, high-margin royalty stream can be viewed as additive to Natera’s longer-term cash-generation narrative. (s201.q4cdn.com)

The court’s ongoing royalty order builds on earlier phases of the dispute, including an injunction issued November 21, 2023, and earlier royalty findings on pre-injunction activity. Investors are also weighing that headline legal wins may not immediately translate into large near-term dollars if the royalty base is limited to sales permitted under specific exceptions to the injunction, or if post-ruling legal maneuvering affects timing. (investor.natera.com)

Traders will focus on whether the royalty base expands or contracts in practice based on how the injunction exceptions are interpreted, how quickly royalties are collected, and whether there are additional legal developments that change the economic terms. Separately, investors will keep attention on execution drivers—volume growth and margin trajectory—alongside 2026 targets outlined by the company. (s201.q4cdn.com)